XTLB
XTL BIOPHARMACEUTICALS LTDMarquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 3× in & out | Q1 2026 | Q2 2026 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at XTL BIOPHARMACEUTICALS LTD. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Dec 3, 2008 — the most recent Form 4 on file — not from today.
- Form 40000909012-08-001242Dec 3, 2008
- Form 40001144204-08-061015Nov 4, 2008
- Form 40001144204-08-061011Nov 4, 2008
- Form 40000909012-08-000731Jun 19, 2008
- Form 40000909012-08-000713Jun 11, 2008
- Form 40000909012-08-000690Jun 6, 2008
- Form 40000909012-08-000571May 6, 2008
- Form 40000909012-08-000560May 2, 2008
- Form 40000909012-08-000523Apr 16, 2008
- Form 40000909012-08-000497Apr 4, 2008
- Form 40000909012-08-000494Apr 2, 2008
- Form 40000909012-08-000455Mar 20, 2008
- Form 40000909012-08-000447Mar 19, 2008
- Form 40000909012-08-000446Mar 19, 2008
- Form 40000909012-08-000425Mar 10, 2008
Fundamentals
XBRL · XTL BIOPHARMACEUTICALS LTDNot enough XBRL history to plot. XTL BIOPHARMACEUTICALS LTDhasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for XTL BIOPHARMACEUTICALS LTD — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMay 22, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMay 15, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMay 7, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERApr 29, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMar 20, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMar 10, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERFeb 27, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERFeb 24, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERFeb 23, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERFeb 17, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERJan 28, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERJan 23, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERJan 23, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERJan 13, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERJan 13, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q1 2026 | Q2 2026 | $0.00 | — | +0% |
| Citadel Advisors | Q2 2025 | Q3 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.